https://www.thebodypro.com/category/lopinavir-ritonavir-kaletra

Lopinavir/Ritonavir (Kaletra)

The Latest

This Week in HIV Research: Looking Forward, Looking Back Img
People Who Use Drugs

This Week in HIV Research: Looking Forward, Looking Back

In our final installment of 2017, we intermingle forward-looking research with some retrospective analysis. We begin our four-study tour by joining researchers in Tennessee for an exercise in HIV outbreak prediction.

Promo Image
CROI (Conference on Retroviruses and Opportunistic Infections)

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study

HIV-positive pregnant women receiving lopinavir/ritonavir-based regimens were at higher risk of preterm delivery compared with those on NNRTI-based regimens.

Slow But Steady Increase in Kidney Risk Observed With TDF, Atazanavir, Lopinavir Img
Kidney

Slow But Steady Increase in Kidney Risk Observed With TDF, Atazanavir, Lopinavir

Each additional year of tenofovir disoproxil fumarate, ritonavir-boosted atazanavir or lopinavir was independently linked to higher incidence of chronic kidney disease in a 23,905-person cohort with initially normal renal function.

Lopinavir/Ritonavir Pellets for Children Tentatively Approved by the FDA Img
News

Lopinavir/Ritonavir Pellets for Children Tentatively Approved by the FDA

On May 21, the U.S. Food and Drug Administration tentatively approved lopinavir/ritonavir 40/10-mg pellets for infants and young children less than 3 years old.

Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results Img
Conference Coverage

Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results

Long-term virologic suppression was superior in children receiving lopinavir/ritonavir-based antiretroviral therapy compared with nevirapine-based regimens at five-year follow up in the IMPAACT P1060 trial.

Promo Image
Bone

Kaletra + Raltegravir: Does Sparing Some Nukes Help Bones?

Once potent combination therapy for HIV (commonly called ART or HAART) is initiated, several clinical trials have found that bone mineral density tends to decrease, usually between 2% and 6%, and then stabilize. The reasons for this initial decrease ...

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy Img
Conference Coverage

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy

A recent study revealed a surprising result: For the first time ever, an HIV treatment regimen consisting of two drugs was found to work just as well as a three-drug regimen.

Promo Image
Conference Coverage

Lopinavir/Ritonavir Monotherapy: The Answer's Still No

At IAS 2013, investigators from the EARNEST trial reported the primary outcome of their study at 96 weeks. Study details are as follows: 1,277 HIV-infected Africans with failure of their first NNRTI-based regimen were randomly assigned to one of thre...

Pharmacokinetics and Acceptability of Lopinavir/Ritonavir Sprinkles in Children Aged 1 to 4 Years Img
Children (Ages 0-17)

Pharmacokinetics and Acceptability of Lopinavir/Ritonavir Sprinkles in Children Aged 1 to 4 Years

It's pretty common knowledge that many prescription drugs -- including HIV meds -- are available as a liquid for children to take. But that's not the only child-friendly drug formulation in the works: Researchers recently tested Kaletra administered ...